Opioids News and Research

RSS
An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.
New formulation of controlled-release drug OxyContin approved

New formulation of controlled-release drug OxyContin approved

Nation's emergency physicians warn parents about dangers of prescription drug abuse

Nation's emergency physicians warn parents about dangers of prescription drug abuse

NMS Labs launches test to evaluate the efficacy of Milnacipran

NMS Labs launches test to evaluate the efficacy of Milnacipran

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Virginia-based medical practice implements CTT's pain therapy medical device

Virginia-based medical practice implements CTT's pain therapy medical device

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Injured nerves may cause severe pain in patients with sickle cell disease

Injured nerves may cause severe pain in patients with sickle cell disease

Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial

Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences to raise $15M in registered direct offering of common stock

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Cancer pain patients: European regulations restricting access to opioid-based drugs

Cancer pain patients: European regulations restricting access to opioid-based drugs

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced

Third party reexamination of Phase III study of Ereska meets primary endpoint

Third party reexamination of Phase III study of Ereska meets primary endpoint

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.